CrossRef Google Scholar Mathews AT, Metaboli OA, Olfert MD, Electrolyte replenishment for athletes PJ, Cuff CF, Disorsers MT, et Metabolic disorders and fat metabolism. You're more likely to have metabolic syndrome if you had diabetes during pregnancy gestational diabetes or if you have a family history of type 2 diabetes. Fatty-acid metabolism disorders result when both parents of the diagnosed subject are carriers of a defective gene.

Metabolic disorders and fat metabolism -

read more , causing confusion or coma. Children become weak and may have vomiting or seizures. Over the long term, children have delayed mental and physical development, an enlarged liver, heart muscle weakness, and an irregular heartbeat.

Sudden death may occur. All states in the United States now require all newborns be screened for MCAD deficiency with a blood test. Tests of the urine and other tissues may also be done. DNA testing can be done to confirm the diagnosis.

Immediate treatment of an MCAD deficiency attack is with dextrose given by vein. For long-term treatment, children must eat often, never skip meals, and consume a diet high in carbohydrates and low in fats.

Supplements of the amino acid carnitine may be helpful. Cornstarch may need to be given at night to prevent the level of glucose in the blood from getting too low. The long-term outcome is generally good. This deficiency is the second most common fatty acid oxidation disorder. It causes symptoms similar to those caused by MCAD deficiency.

People may also have progressive impairment of the structure and function of the muscular walls of the heart chambers cardiomyopathy Overview of Cardiomyopathy Cardiomyopathy refers to progressive impairment of the structure and function of the muscular walls of the heart chambers.

There are 3 main types of cardiomyopathy: Dilated cardiomyopathy, in read more , damage to the nerves of the hands and feet, and abnormal liver function.

When children exert themselves, such as when exercising, the muscle tissue may become destroyed rhabdomyolysis Rhabdomyolysis Rhabdomyolysis occurs when muscle fibers damaged by disease, injury, or toxic substances break down and release their contents into the bloodstream.

Severe disease can cause acute kidney injury read more and the damaged muscles may release the protein myoglobin, which turns the urine brown or bloody myoglobinuria. A woman whose fetus has LCHAD deficiency often has hemolysis the breakdown of red blood cells , elevated levels of liver enzymes indicating liver damage , and a low platelet count called HELLP syndrome HELLP syndrome Preeclampsia is new high blood pressure or worsening of existing high blood pressure that is accompanied by excess protein in the urine and that develops after the 20th week of pregnancy.

read more while pregnant. Doctors diagnose LCHAD deficiency by testing the blood for certain acids. Tests of skin cells are done to look for levels of certain enzymes. Genetic testing Genetic Screening Before Pregnancy Genetic screening is used to determine whether a couple is at increased risk of having a baby with a hereditary genetic disorder.

Hereditary genetic disorders are disorders of chromosomes or read more , which is used to determine whether a couple is at increased risk of having a baby with a hereditary genetic disorder, is also available.

All states in the United States now require all newborns be screened for LCHAD deficiency with a blood test. However, some adults and children can sleep for 8—10 hours through the night without snacking. Carnitor - an L-carnitine supplement that has shown to improve the body's metabolism in individuals with low L-carnitine levels.

It is only useful for Specific fatty-acid metabolism disease. Contents move to sidebar hide. Article Talk. Read Edit View history. Tools Tools.

What links here Related changes Upload file Special pages Permanent link Page information Cite this page Get shortened URL Download QR code Wikidata item.

Download as PDF Printable version. In other projects. Wikimedia Commons. Medical condition. Retrieved doi : PMC PMID June Am J Med Genet C Semin Med Genet. ISSN Classification D. Case—control and cohort studies have found positive associations between several cancers such as prostate cancer[ 67 ], ovarian cancer[ 68 ], breast cancer[ 69 ], colon cancer[ 70 ] etc, and an intake of foods with high levels of saturated fats, such as red meat, eggs, and dairy products.

However, controversial results have also been reported about the role of high fat diet in carcinogenicity [ 71 , 72 ]. This is largely due to the complexity of the diet, not only the fat components such as SFA, MUFA, and PUFA may vary among people in different regions, but also other non-fat nutrients may also alter the function of fat.

Therefore only preclinical animal studies with clearly-defined fat composition may help elucidate the causal relationship between dietary fat and cancer. Up to now, it is generally accepted that cis-MUFA and omega-3 PUFAs are inversely associated with the increased risk of cancer, while SFA and omega-6 PUFAs are associated with the development of cancer [ 73 ].

Interested readers are advised to read recent review articles about the association of dietary lipids with prostate [ 75 ] and breast cancer [ 76 ], and potential mechanisms for the association of dietary lipids with cancer [ 77 - 79 ].

Recent studies have shown that high fat diet with saturated animal fat as major fat in the diet is associated with several cancer such as prostate cancer[ 67 ], colon cancer[ 80 ], ovarian cancer[ 68 ] and breast cancer[ 81 ]etc, whereas high fat diet with plant oils is not associated with cancer risk, however this may not be true, plant oils high in omega-6 fatty acids may be risk factors for cancer, which will be discussed in the polyunsaturated fatty acid section.

It has been found that cancer incidence in the Mediterranean countries, where the main source of fat is olive oil, is lower than in other areas of the world. Such effects may be due to the main MUFA in olive oil, oleic acid, and to certain minor compounds such as squalene and phenolic compounds [ 82 ].

Recent studies have also shown that canola oil, with high MUFA, oleic acid, can decrease colon and breast cancer incidence significantly [ 83 , 84 ]. So far, no epidemiological studies or animal studies can clearly demonstrate the preventive effect of MUFA on cancer, However, in vivo analysis of the fatty acid composition of the adipose tissue of breast cancer and healthy women showed that elevated adipose MUFA, oleic acid, are associated with reduced odds of breast cancer[ 85 ].

Although the mechanism underling the protective function of oleic acid on cancer is, so far, not clear, it has been found that oleic acid, when complexed with the molten globule form of alpha-lactalbumin α-LA , acquires tumoricidal activity [ 86 ].

Increasing evidences from animal and in vitro studies indicate that populations who ingest high amounts of omega-3 fatty acids in their diets have lower incidences of breast, colon, and, perhaps, prostate cancers. Paola et al.

Menéndez et al. However, the clinical roles of omega-3 PUFAs may rely not only on the absolute content but also on the proportion of omega-3 PUFAs to omega-6 PUFAs in the cells due to the inverse biological functions of these two series of PUFAs.

Berquin et al. Although it has been generally accepted that dietary lipids are associated with carcinogenesis and the development of cancer, the detailed mechanism is still far from clear. When lipids are digested and absorbed by small intestine mucosa cells, they can be transported to adipocytes for storage, or used for energy production by peripheral cells through fatty acid β-oxidation.

They can also be used for membrane lipid biosynthesis. Upon environmental stimulus, these lipids may be hydrolyzed and free fatty acidsare released. Omega-6 PUFAs such as ARA released from membrane lipids will be converted to normal eicosanoids, and regulate cellular physiology; however elevated levels of these eicosanoids may accelerate cell proliferation and lead to inflammation and carcinogenesis, etc[ 92 ].

Whereas omega-3 PUFAs such as EPA, when released from membrane lipids, may be converted to eicosanoids with opposite activity to the product of omega-6 fatty acids, which inhibit cell proliferation and COX-2 activity, thus providing cancer preventive function[ 93 ].

Another mechanism of regulation of cancer initiation and development may be elucidated by fatty acid signaling pathway through its receptors. In particular, two transcription factors, sterol regulatory element binding protein-1c SREBP-1c and peroxisome proliferator activated receptor alpha PPAR alpha , have emerged as key mediators of gene regulation by FA [ 94 , 95 ].

SREBP-1c induces a set of lipogenic enzymes in liver. PUFA, but not SFA or MUFA, suppressES the induction of lipogenic genes by inhibiting the expression and processing of SREBP-1c.

Thus inhibits the de novo lipogenesis of fatty acids, which is of particular importance for cancer cells [ 96 ]. PPAR alpha plays an essential role in metabolic adaptation to fasting by inducing the genes for mitochondrial and peroxisomal FA oxidation as well as those for ketogenesis in mitochondria.

FAs released from adipose tissue during fasting are considered as ligands of PPAR alpha. Dietary PUFA, except for n-6, are likely to induce FA oxidation enzymes via PPAR alpha as a "feed-forward " mechanism. PPAR alpha is also required for regulating the synthesis of highly unsaturated FA, indicating pleiotropic functions of PPAR alpha in the regulation of lipid metabolic pathways.

Thus, in addition to its inhibition of fatty acid biosynthesis through SREBP, omega-3 fatty acids induce fatty acid degradation through PPAR alpha, in so doing, they regulate fatty acid metabolism and metabolic diseases.

Multiple mechanisms of omega-3 fatty acids mediated inhibition of cancer may include suppression of neoplastic transformation and cell growth,and enhanced apoptosis and antiangiogenicity etc[ 97 ]. De novo fatty acid biosynthesis occurs in essentially all cells, but adipose tissue and liver are the major sites.

The first committed step in fatty acid synthesis is catalyzed by fatty acid synthase FAS , a multifunctional cytosolic protein that primarily synthesizes palmitate. Variations in FAS expression and enzyme activity have been implicated in insulin resistance and obesity in humans [ 98 ].

A circulating form of FAS has been reported as a biomarker of metabolic stress and insulin sensitivity. In humans it changes with weight loss and may reflect improved insulin sensitivity [ 99 ]. Fatty acid elongation is catalyzed by Elovl elongation of very long-chain fatty acid proteins.

Elovl6 is thought to be involved in de novo lipogenesis and is regulated by dietary, hormonal and developmental factors.

Mice with Elov6 deficiency are obese but protected from insulin resistance [ , ]. Citrate produced by the tricarboxylic acid cycle in mitochondria is converted by ATP-citrate lyase ACL to acetyl-CoA, which is next converted to malonyl-CoA by acetyl CoA carboxylase ACC.

Malonyl-CoA is a potent inhibitor of carnitine- palmitoyl transferase 1 CPT1 , which transports FAs into the mitochondria for oxidation, thus plays a key role in the regulation of both mitochondrial fatty acid oxidation and fat synthesis. ACC catalyzes a key rate-controlling step in both de novo lipogenesis and fatty acid oxidation.

The absence of ACC decreases the cellular concentration of malonyl-CoA, removes the inhibition of CPT1 and maintains FA oxidation.

In rats with NAFLD, suppression or knockdown of ACC isoforms significantly reduced hepatic malonyl-CoA levels, lowered hepatic lipids including long-chain acyl-CoAs, DAG, and triglycerides, and improved hepatic insulin sensitivity [ ].

Lipogenesis and FA oxidation are highly integrated processes. Studies in genetically modified mice have demonstrated that inhibition of FA synthesis and storage is associated with upregulation of FA oxidation [ ].

For examples, knockout the diacylglycerol acyltransferase DGAT , an enzyme that catalyses the final acylation step of TAG synthesis, reduced fat deposition and protected mice against diet- induced obesity and, in the meanwhile, elevated mice energy expenditure and increased activity, suggesting a correlation of disrupted FA storage and increased FA oxidation [ , ].

Similarly, deletion of acetyl-CoA carboxylase 2 ACC2 , an isoform of ACC and key enzyme for de novo FA synthesis, leads to a lean mouse with increased FA oxidation [ ]. As a major component of the metabolic syndrome, NAFLD characterizes with the accumulation of TAGs in hepatocytes, and development of steatohepatitis, cirrhosis, and hepatocellular carcinoma.

FAs stored in adipose tissue and newly made through liver de novo lipogenesis are the major sources of TAGs in the liver [ ]. Lipogenesis is also an insulin- and glucose-dependent process that is under the control of specific transcription factors.

SREBP1 is such a transcription factor and activates most genes involved in FA synthesis. It occurs in two isoforms, SREBP1a and 1c, through alternative splicing. SREBP-1c is highly expressed in the WAT, liver, adrenal gland, brain, and muscle and regulates the expression of many of the genes involved in de novo FA and TAG synthesis including ACC and FAS [ , ].

Insulin increases lipogenesis through activating SREBP-1c that is dependent on the mammalian target of rapamycin mTOR complex 1 mTORC1 [ ].

SREBP1 gene expression is decreased in adipose tissue of obese subjects and the aberrant activation of SREBPs may contribute to obesity-related pathophysiology in various organs, including cardiac arrhythmogenesis and hepatic insulin resistance. Lipogenesis is also regulated by glucose activated carbohydrate response element-binding protein ChREBP , which induces gene expression of liver-type pyruvate kinase, a key regulatory enzyme in glycolysis; this enzyme in turn provides the precursors for lipogenesis [ ].

ChREBP also stimulates expression of genes involved in lipogenesis [ ] including SREBP-1c, which in turn activates glycolytic gene expression, promoting glucose metabolism, and lipogenic genes in conjunction with ChREBP [ ].

ChREBP knockout mice show decreased liver triglyceride but increased liver glycogen content indicating that ChREBP may regulate metabolic gene expression to convert excess carbohydrate into triglyceride rather than glycogen [ ].

Enhanced flux of glucose derivatives through glycolysis, which sustain the redirection of mitochondrial ATP to glucose phosphorylation, and de novo FA synthesis is a hallmark of aggressive cancers. Lipogenic enzymes such as, FAS, ACC, and ACL involved in FA biosynthesis, glycerolphosphate dehydrogenase involved in lipid biosynthesiss, and SREBP1, the master regulator oflipogenicgene expression, are found to be overexpressed in a number of cancer or cancer cells, such as prostate cancer[ ], ovarian cancer[ ], breast cancer[ ], lung cancer[ ], colon cancer[ ], and etc.

Some research has been carried out to provide insights into the molecular mechanism of the association of lipogenesis and cancer. In this chapter we focused on three main lipogenic genes: FAS, ACC, and ACL. High levels of FAS expression have been found in many human cancers, including prostate cancer[ ], ovarian cancer[ , ], breast cancer[ ], bladder cancer[ ], colon cancer[ ] mantle cell lymphoma[ ], and etc.

However, the cellular mechanism by which FAS is up-regulated in cancer cells is not fully understood. Furthermore FAS overexpression is found to be associated with the advanced stage of colorectal cancer and liver metastasis, thus it may also play a role in the progression of cancer[ ].

So far abundant evidences have shown that FAS contributes to both tumorigenesis and metastasis, and it becomes an ideal target for cancer therapy. In deed inhibition of FAS activity by FAS specific inhibitors or siRNA can significantly inhibit cancer or cancer cell growth, induce cancer cell apoptosis, and reduce the metastasis of several cancers[ , ].

Both synthetic chemicals and natural products of FAS inhibitors have been developed [[ ], and the recent progress in developing FAS inhibitors as cancer drugs has been reviewed by Pandey et al[ ]. Apart from FAS, other key lipogenic enzymes for de novo FA biosynthesis include ACL and ACC.

While ACL produce the substrate acetyl-CoA from glycolytic product citrate, ACC activates the substrate to generate malanyl-CoA, the building block for fatty acid synthesis. Both ACC and ACL have been found to be over-expressed in many cancers such as breast, liver, lung, ovarian, prostate and leukemia cancers[ , ].

Inhibition of either ACL or ACC induces growth arrest and apoptosis in several cancer cell lines [ - ]. Yoon et al [ ]found that the major mechanism of HER2-mediated induction of ACC alpha in breast cancer cells is translational regulated primarily through mTOR signaling pathway.

While Mukherjee et al[ ] found that LPA induced induction of ACC in ovarian cancer cells is through LPA2-Gq-PLC-AMPK signaling pathway. Many small molecule inhibitors for ACL and ACC have been developed as potential therapeutic agents for cancer [ , ].

Phospholipids are polar lipids as major component of membrane structure and some intracellular complex such as lipoproteins. Enzymes involved in the metabolism of phospholipids include phospholipase A 2 PLA 2 , phospholipase C PLC , phospholipase D PLD , and lysophospholipase D autotoxin , and alterations of these enzymes have been found to be linked with metabolic diseases, such as MS and cancer.

In addition, the intermediates or end products of phospholipid metabolism such as phosphatidic acid PA , DAG, LPA, sphingosinephoshate SP , and free fatty acid arichidonic acid ARA , are also involved in the pathogenesis of metabolic diseases.

Phosphatidylcholine PC is the most abundant phospholipids in animal cells. Blocking S-adenosylmethionine SAMe or PC synthesis in C. elegans, mouse liver, and human cells have been found to cause elevated SREBPdependent transcription and lipid droplet accumulation [ 4 ], suggesting nutritional or genetic conditions limiting SAMe or PC production may activate SREBP-1, and contribute to human metabolic disorders.

Phosphatidylethanolamine PE is another abundant phospholipid in mammals. PE and its downstream signaling events play an important role in the heart function, and alteration in the asymmetrical transbilayer distribution of PE in sarcolemmal membranes during ischemia causes sarcolemmal disruption [ ].

Moreover, abnormalities in the molecular species profile of PE may contribute to membrane dysfunction and defective contractility of the diabetic heart [ , ]. SREBPs may play critical roles in phospholipid homeostasis and lipotoxic cardiomyopathy. Dysregulated phospholipid signaling that alters SREBP activity has been reported to contribute to the progression of impaired heart function in flies and also act as a potential link to lipotoxic cardiac diseases in humans [ ].

Thus the role of SREBPs in modulating heart function and its associated phospholipid signaling maybe a candidate target for future therapies for obesity- and diabetes- related cardiac dysfunction. An aberrant choline phospholipid metabolism is another major hallmark of cancer cells. In deed alterations of choline phospholipid metabolism have been reported in ovarian cancer and also in breast cancer [ , ].

Altered choline phospholipid metabolism in ovarian cancer has been found to be linked with the regulation of FAS. Phospholipids and their metabolism have been found to be involved in ovarian cancer in several forms, including LPA, PLA 2 , PLD, and autotoxin ATX.

Although aberrant phospholipid metabolism has been found in other cancers, the most detailed research work has been carried out using ovarian cancer as a model, so in this section we summarized the recent advances in the research of phospholipid metabolism and ovarian cancer.

The LPAs, with their various FA side chains, are the constituents of a growth-stimulating factor—ovarian cancer activating factor—that has been identified from ascites in patients with ovarian cancer [ ]. As a bioactive compound, LPA works to induce cell proliferation or differentiation, prevents apoptosis induced by environmental stress or stimuli, induce platelet aggregation and smooth muscle contraction, and stimulate morphological changes, adhesion and migration of cells.

It thus is involved in a broad range of biologic processes in a variety of cellular systems [ , ]. As an established mitogen, LPA also promotes the invasiveness of hepatoma cells into monolayers of mesothelial cells, and stimulates proliferation of ovarian and breast cancer cell lines even in the absence of other growth promoters such as serum.

Furthermore, LPA stimulates rapid neurite retraction and rounding of the cell body in serum-deprived neuroblastoma cells [ ], and plays a critical role in regulation of gene expression in normal and neoplastic cells.

It is a potent modulator of the expression of genes involved in inflammation, angiogenesis, and carcinogenesis such as interleukin [ - ], vascular endothelial growth factor VEGF [ ], urokinase plasminogen activator [ ], and cyclooxygenase-2 [ ].

Thus LPA may contribute to cancer progression by triggering expression of those target genes, resulting in a more invasive and metastatic microenvironment for tumor cells [ , ]. A significant increase in the expression of LPA receptors LPA2 and LPA3 with VEGF was found by Fujita et al.

The recent identification of metabolizing enzymes that mediate the degradation and production of LPA and the development of receptor selective-analogs has opened a potential new approach to the treatment of ovarian cancer [ ].

LPA also stimulates VEGF expression independent of hypoxia-inducible factor 1 H1F1 and promotes tumor angiogenesis by activation of c-Myc and Sp-1 transcription factors [ ]. The PLA 2 enzyme has been implicated in the activation of cell migration and the production of LPA in ovarian carcinoma cells [ ].

Autonomous replication and growth-factor-stimulated proliferation of ovarian cancer cells are highly sensitive to inhibition of calcium-independent PLA 2 iPLA 2 , but are refractory to inhibition of cytosolic PLA 2 [ ].

Activation of iPLA 2 plays a critical role in cell migration, which is involved in many important biologic processes such as development, the immunologic and inflammatory responses, and tumor biology [ ]. In addition to the prominent effect on the cell cycle, inhibition of iPLA 2 also induced weak-to-modest increases in apoptosis [ ].

Downregulation of iPLA 2 with lentivirus-mediated RNA interference targeting iPLA 2 expression inhibited cell proliferation in culture and decreased tumorigenicity of ovarian cancer cell lines in athymic nude mice [ ].

Recently iPLA 2 has been found to play a role in breast cancer metastasis as iPLA 2 deficiency protects breast cancer from metastasis to the lung [ ].

PLD, a family of signaling enzymes that most commonly responsible to generate most lipid second messenger phosphatidic acid PA , is found in diverse organisms from bacteria to humans and functions in multiple cellular pathways. It has been increasingly recognized as a critical regulator of cell proliferation and tumorigenesis and the expression and activity of PLD are elevated in many different types of human cancers.

In ovarian cancer cells, PLD is involved in the formation of PA, which may be further converted to LPA by PLA 2. It was suggested that PLD is also involved in cancer progression and metastasis and elevated PLD expression has been reported in various cancer tissues [ ].

Moreover, PLD was found to stimulate cell protrusions in v-Src—transformed cells [ ]. Furthermore, PLD activity was elevated by the integrin receptor signaling pathway in OVCAR-3 cells, and PLD blocking was found to inhibit integrin-mediated Rac translocation in, and the spreading and migration of, OVCAR-3 cells [ ].

Thus, the PLD-PA-Rac pathway plays an important role in the metastasis of cancer cells, and might provide a connection for integrin and PLD-mediated cancer metastasis [ ]. The ATX protein is a member of the ectonucleotide pyrophosphatase and phosphodiesterase family of enzymes, but unlike other members of this group, ATX possesses lysophospholipase D activity.

This enzyme hydrolyzes lysophosphatidylcholine LPC to generate bioactive lipid LPA, which is an important signaling molecule regulates a variety of biological process through its receptors.

ATX is essential for normal development and is implicated in various physiological processes. It also acts as a potent tumor growth factor and mitogen that is, associated with pathological conditions such as cancer, pain and fibrosis.

Exogenous addition of VEGF-A to cultured cells induces ATX expression and secretion, resulting in increased extracellular LPA production [ ]. This elevated LPA, acting through LPA4, modulates VEGF responsiveness by inducing VEGF receptor 2 expression.

Downregulation of ATX secretion in SKOV3 cells significantly attenuates cell motility responses to VEGF, ATX, LPA, LPC [ ]. Through their respective G protein—coupled receptors, LPC and LPA have both been reported to stimulate migration [ ].

LPC was unable to stimulate the cellular migration by itself, ATX had to be present. Knocking down ATX secretion, or inhibiting its catalytic activity, blocked cellular migration by preventing LPA production and the subsequent activation of LPA receptors [ ]. As a combination of central obesity, dyslipidemia, and insulin resistance, MS is the central of world—wide prevalence of Type 2 Diabetes Mellitus T2DM , cardiovascular diseases and inflammation.

Current animal and clinical evidence strongly suggest that abnormal lipid metabolism is closely associated with onset of insulin resistance and cancer. Importantly, more and more evidence show that most of the components of the MS are linked in some way to the development of various cancers [ - ], although epidemiological studies linking the MS to cancer are highly required.

Obesity and diabetes have been reported to be associated with breast, endometrial, colorectal, pancreatic, hepatic or renal cancer [ , ]. However, the mechanisms by which actually promote tumor cell growth in patients with MS need further investigation.

Since lipids and their metabolites and metabolism pathways are related to metabolic diseases and cancer cell growth, we propose that lipids may link to MS and cancers and exploring the related molecules and understanding the underlying mechanisms will be helpful in developing potential therapies for both MS and cancer.

Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution 3. Edited by Rodrigo Valenzuela Baez.

Open access Lipid Metabolism, Metabolic Syndrome, and Cancer Written By Fang Hu, Yingtong Zhang and Yuanda Song. DOWNLOAD FOR FREE Share Cite Cite this chapter There are two ways to cite this chapter:.

Choose citation style Select style Vancouver APA Harvard IEEE MLA Chicago Copy to clipboard Get citation. Choose citation style Select format Bibtex RIS Download citation. IntechOpen Lipid Metabolism Edited by Rodrigo Valenzuela Baez.

From the Edited Volume Lipid Metabolism Edited by Rodrigo Valenzuela Baez Book Details Order Print. Chapter metrics overview 6, Chapter Downloads View Full Metrics. Impact of this chapter. Introduction Metabolism is the process of making energy and cellular molecules from breaking down the food that made up of proteins, carbohydrates and fats etc.

Dietary lipids and metabolic syndrome MS, also known as syndrome X, or the insulin resistance syndrome, is a combination of medical disorders comprising an array of metabolic risk factors including central obesity, dyslipidemia, hypertension, glucose intolerance, and insulin resistance[ 7 ].

Fatty acids and insulin resistance Insulin resistance is the center underlying the different metabolic abnormalities in the metabolic syndrome, in which pathophysiological conditions insulin becomes less effective in lowering blood glucose.

Fatty acids and cardiovascular diseases Since the s, it has long been believed that consumption of foods containing high amounts of SFAs, including meat fats, milk fat, butter, lard, coconut oil, etc, is not only a risk factor for dyslipidemia and insulin resistance, but also a risk factor for cardiovascular diseases.

Dietary lipids and cancer Case—control and cohort studies have found positive associations between several cancers such as prostate cancer[ 67 ], ovarian cancer[ 68 ], breast cancer[ 69 ], colon cancer[ 70 ] etc, and an intake of foods with high levels of saturated fats, such as red meat, eggs, and dairy products.

Saturated fatty acids Recent studies have shown that high fat diet with saturated animal fat as major fat in the diet is associated with several cancer such as prostate cancer[ 67 ], colon cancer[ 80 ], ovarian cancer[ 68 ] and breast cancer[ 81 ]etc, whereas high fat diet with plant oils is not associated with cancer risk, however this may not be true, plant oils high in omega-6 fatty acids may be risk factors for cancer, which will be discussed in the polyunsaturated fatty acid section.

Monounsaturated fatty acids It has been found that cancer incidence in the Mediterranean countries, where the main source of fat is olive oil, is lower than in other areas of the world.

Polyunsaturated fatty acids Increasing evidences from animal and in vitro studies indicate that populations who ingest high amounts of omega-3 fatty acids in their diets have lower incidences of breast, colon, and, perhaps, prostate cancers.

Potential mechanisms of the association of dietary lipids with cancer Although it has been generally accepted that dietary lipids are associated with carcinogenesis and the development of cancer, the detailed mechanism is still far from clear.

De novo lipogenesis in metabolic syndrome De novo fatty acid biosynthesis occurs in essentially all cells, but adipose tissue and liver are the major sites. De novo lipogenesis in cancer Enhanced flux of glucose derivatives through glycolysis, which sustain the redirection of mitochondrial ATP to glucose phosphorylation, and de novo FA synthesis is a hallmark of aggressive cancers.

Fatty acid synthase High levels of FAS expression have been found in many human cancers, including prostate cancer[ ], ovarian cancer[ , ], breast cancer[ ], bladder cancer[ ], colon cancer[ ] mantle cell lymphoma[ ], and etc.

ATP-Citrate lyase and acetyl CoA carboxylase Apart from FAS, other key lipogenic enzymes for de novo FA biosynthesis include ACL and ACC. Phospholipid metabolism in metabolic syndrome Phosphatidylcholine PC is the most abundant phospholipids in animal cells.

Phospholipid metabolism in cancer An aberrant choline phospholipid metabolism is another major hallmark of cancer cells.

Lysophosphatidic acid The LPAs, with their various FA side chains, are the constituents of a growth-stimulating factor—ovarian cancer activating factor—that has been identified from ascites in patients with ovarian cancer [ ].

Phospholipase A 2 The PLA 2 enzyme has been implicated in the activation of cell migration and the production of LPA in ovarian carcinoma cells [ ]. Phospholipase D PLD, a family of signaling enzymes that most commonly responsible to generate most lipid second messenger phosphatidic acid PA , is found in diverse organisms from bacteria to humans and functions in multiple cellular pathways.

Autotaxin The ATX protein is a member of the ectonucleotide pyrophosphatase and phosphodiesterase family of enzymes, but unlike other members of this group, ATX possesses lysophospholipase D activity. References 1. Kiebish M. et al. J Lipid Res. Swinnen J. Verhoeven G. J Steroid Biochem Mol Biol.

Lee C. Olson Evans R. Walker A. Podo F. NMR Biomed. Pegorier J. Am J Physiol. Eckel R. Grundy Zimmet P. Unger R H Lipotoxic diseases. Annu Rev Med. Unger R. Scherer P. Trends Endocrinol Metab. Hotamisligil G. Budavari A. Ellis R. White M. BM Spiegelman IRSmediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance.

Schinner S.

A Metabolic disorders and fat metabolism classification for genetic disorders that xnd from an inability of the body to produce or utilize xisorders enzyme or transport protein metaholism is Maximum calorie burn exercises to oxidize fatty acids. They are an inborn error of Metabolic disorders and fat metabolism metabolismand when disordefs affects the muscles also a metabolic myopathy. The enzyme or transport protein can be missing or improperly constructed, resulting in it not working. This leaves the body unable to produce energy within the liver and muscles from fatty acid sources. The body's primary source of energy is glucose; however, when all the glucose in the body has been expended, a normal body digests fats. Individuals with a fatty-acid metabolism disorder are unable to metabolize this fat source for energy, halting bodily processes.

Metabolic disorders and fat metabolism -

Proc Natl Acad Sci USA 94 : — Kliewer SA , Lenhard JM , Willson TM , Patel I , Morris DC , Lehmann JM A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation.

Kliewer SA , Sundseth SS , Jones SA , Brown PJ , Wisely GB , Koble CS , Devchand P , Wahli W , Willson TM , Lenhard JM , Lehmann JM Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ.

Mol Endocrinol 11 : — Chawla A , Repa JJ , Evans RM , Mangelsdorf DJ Nuclear receptors and lipid physiology: opening the X-files. Science : — Dreyer C , Keller H , Mahfoudi A , Laudet V , Krey G , Wahli W Positive regulation of the peroxisomal β-oxidation pathway by fatty acids through activation of peroxisome proliferator-activated receptors PPAR.

Biol Cell 77 : 67 — Peters JM , Hennuyer N , Staels B , Fruchart JC , Fievet C , Gonzalez FJ , Auwerx J Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor α-deficient mice.

J Biol Chem : — Barak Y , Nelson MC , Ong ES , Jones YZ , Ruiz-Lozano P , Chien KR , Koder A , Evans RM PPAR γ is required for placental, cardiac, and adipose tissue development. Mol Cell 4 : — Kubota N , Terauchi Y , Miki H , Tamemoto H , Yamauchi T , Komeda K , Satoh S , Nakano R , Ishii C , Sugiyama T , Eto K , Tsubamoto Y , Okuno A , Murakami K , Sekihara H , Hasegawa G , Naito M , Toyoshima Y , Tanaka S , Shiota K , Kitamura T , Fujita T , Ezaki O , Aizawa S , Kadowaki T PPAR γ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance.

Rosen ED , Sarraf P , Troy AE , Bradwin G , Moore K , Milstone DS , Spiegelman BM , Mortensen RM PPAR γ is required for the differentiation of adipose tissue in vivo and in vitro.

Michalik L , Desvergne B , Tan NS , Basu-Modak S , Escher P , Rieusset J , Peters JM , Kaya G , Gonzalez FJ , Zakany J , Metzger D , Chambon P , Duboule D , Wahli W Impaired skin wound healing in peroxisome proliferator-activated receptor PPAR α and PPARβ mutant mice. J Cell Biol : — Genes Dev 15 : — Di-Poi N , Tan NS , Michalik L , Wahli W , Desvergne B Antiapoptotic role of PPARβ in keratinocytes via transcriptional control of the Akt1 signaling pathway.

Mol Cell 10 : — Chawla A , Lee CH , Barak Y , He W , Rosenfeld J , Liao D , Han J , Kang H , Evans RM PPARδ is a very low-density lipoprotein sensor in macrophages.

Proc Natl Acad Sci USA : — Lee SS , Pineau T , Drago J , Lee EJ , Owens JW , Kroetz DL , Fernandez-Salguero PM , Westphal H , Gonzalez FJ Targeted disruption of the α isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators.

Mol Cell Biol 15 : — Lehmann JM , Moore LB , Smith-Oliver TA , Wilkison WO , Willson TM , Kliewer SA An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ PPAR γ.

Leone TC , Weinheimer CJ , Kelly DP A critical role for the peroxisome proliferator-activated receptor α PPARα in the cellular fasting response: the PPARα-null mouse as a model of fatty acid oxidation disorders.

Proc Natl Acad Sci USA 96 : — Kersten S , Seydoux J , Peters JM , Gonzalez FJ , Desvergne B , Wahli W Peroxisome proliferator-activated receptor α mediates the adaptive response to fasting.

J Clin Invest : — Αoyama T , Peters JM , Iritani N , Nakajima T , Furihata K , Hashimoto T , Gonzalez FJ Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor α PPARα.

Watts GF , Dimmitt SB Fibrates, dyslipoproteinaemia and cardiovascular disease. Curr Opin Lipidol 10 : — Finck BN , Lehman JJ , Leone TC , Welch MJ , Bennett MJ , Kovacs A , Han X , Gross RW , Kozak R , Lopaschuk GD , Kelly DP The cardiac phenotype induced by PPARα overexpression mimics that caused by diabetes mellitus.

Finck BN , Han X , Courtois M , Aimond F , Nerbonne JM , Kovacs A , Gross RW , Kelly DP A critical role for PPARα-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content.

Tordjman K , Bernal-Mizrachi C , Zemany L , Weng S , Feng C , Zhang F , Leone TC , Coleman T , Kelly DP , Semenkovich CF PPARα deficiency reduces insulin resistance and atherosclerosis in apoE-null mice.

Tontonoz P , Hu E , Spiegelman BM Stimulation of adipogenesis in fibroblasts by PPAR γ 2, a lipid-activated transcription factor.

Cell 79 : — Sood V , Colleran K , Burge MR Thiazolidinediones: a comparative review of approved uses. Diabetes Technol Ther 2 : — Way JM , Harrington WW , Brown KK , Gottschalk WK , Sundseth SS , Mansfield TA , Ramachandran RK , Willson TM , Kliewer SA Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues.

Endocrinology : — Tontonoz P , Hu E , Graves RA , Budavari AI , Spiegelman BM mPPAR γ 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 8 : — Young PW , Cawthorne MA , Coyle PJ , Holder JC , Holman GD , Kozka IJ , Kirkham DM , Lister CA , Smith SA Repeat treatment of obese mice with BRL , a new potent insulin sensitizer, enhances insulin action in white adipocytes.

Association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling. Diabetes 44 : — Prostaglandins Leukot Essent Fatty Acids 57 : 17 — Schoonjans K , Peinado-Onsurbe J , Lefebvre AM , Heyman RA , Briggs M , Deeb S , Staels B , Auwerx J PPARα and PPARγ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene.

EMBO J 15 : — Ribon V , Johnson JH , Camp HS , Saltiel AR Thiazolidinediones and insulin resistance: peroxisome proliferator activated receptor γ activation stimulates expression of the CAP gene. Proc Natl Acad Sci USA 95 : — Martin G , Schoonjans K , Lefebvre AM , Staels B , Auwerx J Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARα and PPARγ activators.

Guan HP , Li Y , Jensen MV , Newgard CB , Steppan CM , Lazar MA A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nat Med 8 : — Aubert J , Champigny O , Saint-Marc P , Negrel R , Collins S , Ricquier D , Ailhaud G Up-regulation of UCP-2 gene expression by PPAR agonists in preadipose and adipose cells.

Biochem Biophys Res Commun : — Randle PJ Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. Diabetes Metab Rev 14 : — De Vos P , Lefebvre AM , Miller SG , Guerre-Millo M , Wong K , Saladin R , Hamann LG , Staels B , Briggs MR , Auwerx J Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor γ.

J Clin Invest 98 : — Kallen CB , Lazar MA Antidiabetic thiazolidinediones inhibit leptin ob gene expression in 3T3—L1 adipocytes.

Proc Natl Acad Sci USA 93 : — Miles PD , Romeo OM , Higo K , Cohen A , Rafaat K , Olefsky JM TNF-α-induced insulin resistance in vivo and its prevention by troglitazone. Diabetes 46 : — Peraldi P , Xu M , Spiegelman BM Thiazolidinediones block tumor necrosis factor-α-induced inhibition of insulin signaling.

Yamauchi T , Kamon J , Waki H , Terauchi Y , Kubota N , Hara K , Mori Y , Ide T , Murakami K , Tsuboyama-Kasaoka N , Ezaki O , Akanuma Y , Gavrilova O , Vinson C , Reitman ML , Kagechika H , Shudo K , Yoda M , Nakano Y , Tobe K , Nagai R , Kimura S , Tomita M , Froguel P , Kadowaki T The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity.

Nat Med 7 : — Maeda N , Takahashi M , Funahashi T , Kihara S , Nishizawa H , Kishida K , Nagaretani H , Matsuda M , Komuro R , Ouchi N , Kuriyama H , Hotta K , Nakamura T , Shimomura I , Matsuzawa Y PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein.

Diabetes 50 : — Berg AH , Combs TP , Du X , Brownlee M , Scherer PE The adipocyte-secreted protein Acrp30 enhances hepatic insulin action.

Burant CF , Sreenan S , Hirano K , Tai TA , Lohmiller J , Lukens J , Davidson NO , Ross S , Graves RA Troglitazone action is independent of adipose tissue. Chao L , Marcus-Samuels B , Mason MM , Moitra J , Vinson C , Arioglu E , Gavrilova O , Reitman ML Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones.

Memon RA , Tecott LH , Nonogaki K , Beigneux A , Moser AH , Grunfeld C , Feingold KR Up-regulation of peroxisome proliferator-activated receptors PPAR-α and PPAR-γ messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-γ-responsive adipose tissue-specific genes in the liver of obese diabetic mice.

Nagy L , Tontonoz P , Alvarez JG , Chen H , Evans RM Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ.

Cell 93 : — Chawla A , Boisvert WA , Lee CH , Laffitte BA , Barak Y , Joseph SB , Liao D , Nagy L , Edwards PA , Curtiss LK , Evans RM , Tontonoz P A PPAR γ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 7 : — Repa JJ , Turley SD , Lobaccaro JA , Medina J , Li L , Lustig K , Shan B , Heyman RA , Dietschy JM , Mangelsdorf DJ Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers.

Venkateswaran A , Laffitte BA , Joseph SB , Mak PA , Wilpitz DC , Edwards PA , Tontonoz P Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR α. Proc Natl Acad Sci USA 97 : — Li AC , Brown KK , Silvestre MJ , Willson TM , Palinski W , Glass CK Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice.

Collins AR , Meehan WP , Kintscher U , Jackson S , Wakino S , Noh G , Palinski W , Hsueh WA , Law RE Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice.

Arterioscler Thromb Vasc Biol 21 : — Chen Z , Ishibashi S , Perrey S , Osuga Ji, Gotoda T , Kitamine T , Tamura Y , Okazaki H , Yahagi N , Iizuka Y , Shionoiri F , Ohashi K , Harada K , Shimano H , Nagai R , Yamada N Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL.

Claudel T , Leibowitz MD , Fievet C , Tailleux A , Wagner B , Repa JJ , Torpier G , Lobaccaro JM , Paterniti JR , Mangelsdorf DJ , Heyman RA , Auwerx J Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor.

Proc Natl Acad Sci USA 98 : — Lee CH , Evans RM Peroxisome proliferator-activated receptor-γ in macrophage lipid homeostasis. Trends Endocrinol Metab 13 : — Muoio DM , MacLean PS , Lang DB , Li S , Houmard JA , Way JM , Winegar DA , Corton JC , Dohm GL , Kraus WE Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator-activated receptor PPAR α knock-out mice.

Evidence for compensatory regulation by PPAR δ. Barak Y , Liao D , He W , Ong ES , Nelson MC , Olefsky JM , Boland R , Evans RM Effects of peroxisome proliferator-activated receptor δ on placentation, adiposity, and colorectal cancer.

Proc Natl Acad Sci USA 99 : — Peters JM , Lee SS , Li W , Ward JM , Gavrilova O , Everett C , Reitman ML , Hudson LD , Gonzalez FJ Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor β δ.

Mol Cell Biol 20 : — Oliver Jr WR , Shenk JL , Snaith MR , Russell CS , Plunket KD , Bodkin NL , Lewis MC , Winegar DA , Sznaidman ML , Lambert MH , Xu HE , Sternbach DD , Kliewer SA , Hansen BC , Willson TM A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport.

Londos C , Brasaemle DL , Schultz CJ , Segrest JP , Kimmel AR Perilipins, ADRP, and other proteins that associate with intracellular neutral lipid droplets in animal cells. Semin Cell Dev Biol 10 : 51 — Ginsberg HN New perspectives on atherogenesis: role of abnormal triglyceride-rich lipoprotein metabolism.

Circulation : — Vosper H , Patel L , Graham TL , Khoudoli GA , Hill A , Macphee CH , Pinto I , Smith SA , Suckling KE , Wolf CR , Palmer CN The peroxisome proliferator-activated receptor δ promotes lipid accumulation in human macrophages.

Oberfield JL , Collins JL , Holmes CP , Goreham DM , Cooper JP , Cobb JE , Lenhard JM , Hull-Ryde EA , Mohr CP , Blanchard SG , Parks DJ , Moore LB , Lehmann JM , Plunket K , Miller AB , Milburn MV , Kliewer SA , Willson TM A peroxisome proliferator-activated receptor γ ligand inhibits adipocyte differentiation.

Rocchi S , Picard F , Vamecq J , Gelman L , Potier N , Zeyer D , Dubuquoy L , Bac P , Champy MF , Plunket KD , Leesnitzer LM , Blanchard SG , Desreumaux P , Moras D , Renaud JP , Auwerx J A unique PPARγ ligand with potent insulin-sensitizing yet weak adipogenic activity.

Mol Cell 8 : — Berger JP , Petro AE , MacNaul KL , Kelly LJ , Zhang BB , Richards K , Elbrecht A , Johnson BA , Zhou G , Doebber TW , Biswas C , Parikh M , Sharma N , Tanen MR , Thompson GM , Ventre J , Adams AD , Mosley R , Surwit RS , Moller DE Distinct properties and advantages of a novel PPARγ selective modulator.

Mol Endocrinol 17 : — J Med Chem 45 : — Am J Physiol Endocrinol Metab : E — E Oxford University Press is a department of the University of Oxford.

It furthers the University's objective of excellence in research, scholarship, and education by publishing worldwide. Sign In or Create an Account. Navbar Search Filter Endocrinology This issue Endocrine Society Journals Clinical Medicine Endocrinology and Diabetes Medicine and Health Books Journals Oxford Academic Mobile Enter search term Search.

Endocrine Society Journals. Advanced Search. Search Menu. Article Navigation. Close mobile search navigation Article Navigation. Volume Article Contents Abstract. PPAR γ. Journal Article. Minireview: Lipid Metabolism, Metabolic Diseases, and Peroxisome Proliferator-Activated Receptors. Chih-Hao Lee , Chih-Hao Lee.

Oxford Academic. Peter Olson. Ronald M. Evans, Ph. and P. contributed equally to this work. PDF Split View Views. Cite Cite Chih-Hao Lee, Peter Olson, Ronald M.

Select Format Select format. ris Mendeley, Papers, Zotero. enw EndNote. bibtex BibTex. txt Medlars, RefWorks Download citation. Permissions Icon Permissions. Close Navbar Search Filter Endocrinology This issue Endocrine Society Journals Clinical Medicine Endocrinology and Diabetes Medicine and Health Books Journals Oxford Academic Enter search term Search.

Abstract Lipid and carbohydrate homeostasis in higher organisms is under the control of an integrated system that has the capacity to rapidly respond to metabolic changes.

Figure 1. Open in new tab Download slide. Figure 2. phosphoenolpyruvate carboxykinase;. peroxisome proliferator-activated receptors;.

Google Scholar Crossref. Search ADS. Google Scholar PubMed. OpenURL Placeholder Text. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ.

A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay.

Positive regulation of the peroxisomal β-oxidation pathway by fatty acids through activation of peroxisome proliferator-activated receptors PPAR. Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor α-deficient mice. PPAR γ is required for placental, cardiac, and adipose tissue development.

PPAR γ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. PPAR γ is required for the differentiation of adipose tissue in vivo and in vitro. Impaired skin wound healing in peroxisome proliferator-activated receptor PPAR α and PPARβ mutant mice. Antiapoptotic role of PPARβ in keratinocytes via transcriptional control of the Akt1 signaling pathway.

Targeted disruption of the α isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators.

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ PPAR γ. A critical role for the peroxisome proliferator-activated receptor α PPARα in the cellular fasting response: the PPARα-null mouse as a model of fatty acid oxidation disorders.

Peroxisome proliferator-activated receptor α mediates the adaptive response to fasting. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor α PPARα.

The cardiac phenotype induced by PPARα overexpression mimics that caused by diabetes mellitus. A critical role for PPARα-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content.

PPARα deficiency reduces insulin resistance and atherosclerosis in apoE-null mice. Stimulation of adipogenesis in fibroblasts by PPAR γ 2, a lipid-activated transcription factor. Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues.

Repeat treatment of obese mice with BRL , a new potent insulin sensitizer, enhances insulin action in white adipocytes. PPARα and PPARγ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. Thiazolidinediones and insulin resistance: peroxisome proliferator activated receptor γ activation stimulates expression of the CAP gene.

Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARα and PPARγ activators. Up-regulation of UCP-2 gene expression by PPAR agonists in preadipose and adipose cells. Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years.

Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor γ. Antidiabetic thiazolidinediones inhibit leptin ob gene expression in 3T3—L1 adipocytes. TNF-α-induced insulin resistance in vivo and its prevention by troglitazone.

Thiazolidinediones block tumor necrosis factor-α-induced inhibition of insulin signaling. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity.

PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. Up-regulation of peroxisome proliferator-activated receptors PPAR-α and PPAR-γ messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-γ-responsive adipose tissue-specific genes in the liver of obese diabetic mice.

Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ. A PPAR γ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers.

Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR α. Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice.

Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Alcohol induces more severe fatty liver disease by influencing cholesterol metabolism. Evid-Based Complement Alternat Med. Wong VW-S, Singal AK. Emerging medical therapies for non-alcoholic fatty liver disease and for alcoholic hepatitis.

Transl Gastroenterol Hepatol. Barb D, Portillo-Sanchez P, Cusi K. Pharmacological management of nonalcoholic fatty liver disease. Rana R, Shearer AM, Fletcher EK, Nguyen N, Guha S, Cox DH, et al. PAR2 controls cholesterol homeostasis and lipid metabolism in nonalcoholic fatty liver disease.

Mol Metab. Yaribeygi H, Farrokhi FR, Butler AE, Sahebkar A. Insulin resistance: review of the underlying molecular mechanisms. J Cell Physiol. Neuenschwander M, Ballon A, Weber KS, Norat T, Aune D, Schwingshackl L, et al.

Role of diet in type 2 diabetes incidence: umbrella review of meta-analyses of prospective observational studies. Liu J, Liu Z. Muscle insulin resistance and the inflamed microvasculature: fire from within. Int J Mol Sci. Ekpenyong CE. Relationship between insulin resistance and metabolic syndrome clusters: current knowledge.

Acta Sci Med Sci. Yan Y-Z, Ma R-L, Zhang J-Y, He J, Ma J-L, Pang H-R, et al. Association of insulin resistance with glucose and lipid metabolism: ethnic heterogeneity in far Western China.

Mediat Inflamm. Li T, Chen K, Liu G, Huang L-P, Chen L, Wang Q-W, et al. Calorie restriction prevents the development of insulin resistance and impaired lipid metabolism in gestational diabetes offspring.

Pediatr Res. J-a K, Wei Y, Sowers JR. Role of mitochondrial dysfunction in insulin resistance. Circ Res. Mitochondrial Dys function and insulin resistance: from pathophysiological molecular mechanisms to the impact of diet.

Front Physiol. Szendroedi J, Yoshimura T, Phielix E, Koliaki C, Marcucci M, Zhang D, et al. Role of diacylglycerol activation of PKCθ in lipid-induced muscle insulin resistance in humans.

Proc Natl Acad Sci. Sokolowska E, Błachnio-Zabielska AU. The role of ceramides in insulin resistance. Mathews AT, Famodu OA, Olfert MD, Murray PJ, Cuff CF, Downes MT, et al. Efficacy of nutritional interventions to lower circulating ceramides in young adults: FRUVEDomic pilot study.

Physiol Rep. Laganà AS, Rossetti P, Buscema M, La Vignera S, Condorelli RA, Gullo G, et al. Metabolism and ovarian function in PCOS women: a therapeutic approach with inositols. Int J Endocrinol. Lath R, Shendye R, Jibhkate A. Insulin resistance and lipid profile in polycystic ovary syndrome.

Asian J Biomed Pharm Sci. Whigham DL, Butz ED, Dashti H, Tonelli M, Johnson KL, Cook EM, et al. Metabolic evidence of diminished lipid oxidation in women with polycystic ovary syndrome.

Curr Metabolomics. Li S, Chu Q, Ma J, Sun Y, Tao T, Huang R, et al. Discovery of novel lipid profiles in PCOS: do insulin and androgen oppositely regulate bioactive lipid production? J Clin Endocrinol Metab. CAS Google Scholar. Chandrasekaran S, Sagili H.

Metabolic syndrome in women with polycystic ovary syndrome. Obstet Gynaecol. Liu Q, Xie Y-J, Qu L-H, Zhang M-X, Mo Z-C. Dyslipidemia involvement in the development of polycystic ovary syndrome. Taiwan J Obstet Gynecol. Pundir J, Charles D, Sabatini L, Hiam D, Jitpiriyaroj S, Teede H, et al.

Overview of systematic reviews of non-pharmacological interventions in women with polycystic ovary syndrome. Hum Reprod Update. Shamim A, Mahmood T, Ahsan F, Kumar A, Bagga P. Lipids: An insight into the neurodegenerative disorders. Clin Nutr Exp. Noronha S, Lima P, Campos G, Chírico M, Abreu A, Figueiredo A, et al.

Association of high-fat diet with neuroinflammation, anxiety-like defensive behavioral responses, and altered thermoregulatory responses in male rats.

Brain Behav Immun. Guillemot-Legris O, Muccioli GG. Obesity-induced neuroinflammation: beyond the hypothalamus. Trends Neurosci. Radtke FA, Chapman G, Hall J, Syed YA. Modulating neuroinflammation to treat neuropsychiatric disorders.

Joffre C. Polyunsaturated fatty acid metabolism in the brain and brain cells. Feed your mind-how does nutrition modulate brain function throughout life? IntechOpen; Orio L, Alen F, Pavón FJ, Serrano A, García-Bueno B.

Oleoylethanolamide, neuroinflammation and alcohol abuse. Front Mol Neurosci. Download references. Department of Pharmacy, University of Agriculture Faisalabad, Faisalabad, Pakistan.

Department of Pharmaceutical Chemistry, Government College University Faisalabad, Faisalabad, Pakistan. You can also search for this author in PubMed Google Scholar. Department of Chemistry, COMSATS University Islamabad, Islamabad, Pakistan.

Reprints and permissions. Haider, K. Impaired Lipid Metabolism in Metabolic Disorders. In: Akash, M. eds Endocrine Disrupting Chemicals-induced Metabolic Disorders and Treatment Strategies. Emerging Contaminants and Associated Treatment Technologies. Springer, Cham. Published : 05 August Publisher Name : Springer, Cham.

Print ISBN : Online ISBN : eBook Packages : Earth and Environmental Science Earth and Environmental Science R0. Anyone you share the following link with will be able to read this content:. Sorry, a shareable link is not currently available for this article. Provided by the Springer Nature SharedIt content-sharing initiative.

Policies and ethics. Skip to main content. Abstract Metabolic disorders relating to impaired lipid metabolism have become an annoying issue in current era. Keywords Bioactive lipids Insulin resistance Metabolic syndrome Lipid homeostasis.

Buying options Chapter EUR eBook EUR Softcover Book EUR Hardcover Book EUR Tax calculation will be finalised at checkout Purchases are for personal use only Learn about institutional subscriptions. References Aguilar-Salinas CA, Viveros-Ruiz T.

CrossRef Google Scholar Fornari E, Maffeis C. CrossRef Google Scholar Metcalfe LK, Smith GC, Turner N. CrossRef CAS Google Scholar Dejman A, Riveros J. CrossRef Google Scholar Jung B, Martinez M, Claessens Y-E, Darmon M, Klouche K, Lautrette A, et al.

CrossRef Google Scholar Gregory JW. CrossRef Google Scholar Gao M, Liu D. CrossRef Google Scholar Kim D, Touros A, Kim WR.

CrossRef Google Scholar Khawandanah J. CrossRef Google Scholar Urbanovych A, Kozlovska K, Urbanovych M. Google Scholar Pradas I, Rovira-Llopis S, Naudí A, Bañuls C, Rocha M, Hernandez-Mijares A, et al.

CrossRef CAS Google Scholar Hallett PJ, Engelender S, Isacson O. CrossRef Google Scholar Naifeh J, Varacallo M. Google Scholar Lund J, Aas V, Tingstad RH, Van Hees A, Nikolić N. CrossRef Google Scholar Sun S, Li H, Chen J, Qian Q. CrossRef CAS Google Scholar Lazzeri C, Valente S, Chiostri M, Gensini GF.

CrossRef Google Scholar Stocker RA. Google Scholar Liu C, Wu J, Zhu J, Kuei C, Yu J, Shelton J, et al. CrossRef CAS Google Scholar Yonejima Y, Ushida K, Mori Y. CrossRef Google Scholar Fruh SM. CrossRef Google Scholar Blüher M. CrossRef Google Scholar Sivamaruthi BS, Kesika P, Suganthy N, Chaiyasut C.

CrossRef Google Scholar Broussard J, Brady MJ. CrossRef CAS Google Scholar Hirotsu C, Tufik S, Andersen ML. CrossRef Google Scholar Taheri S. CrossRef CAS Google Scholar Mahat B, Chassé É, Mauger J-F, Imbeault P. CrossRef Google Scholar Paudel MS, Tiwari A, Mandal A, Shrestha B, Kafle P, Chaulagai B, et al.

Google Scholar Janardhan SV. CrossRef Google Scholar Mato JM, Alonso C, Noureddin M, Lu SC. CrossRef CAS Google Scholar Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P.

Metabolic disorders Low-carb and anti-aging benefits to impaired disofders metabolism have metabolis an Metabolic disorders and fat metabolism issue metabopism current era. Energy dense diet coupled disoorders sedentary life-style Metabolic disorders and fat metabolism crucial triggering events for metsbolism metabolic fst that significantly disturb various metabolic pathways notably carbohydrate and lipid homeostasis. The ultimately developed metabolic syndromes such as lactic acidosis, obesity, non-alcoholic fatty liver disease, type 2 diabetes, polycystic ovaries, and neurodegenerative disorders are potential health risks that disturb the quality of life. Deposition of lipids in the non-adipose tissues such as muscle and liver is also strongly interlinked with insulin resistance. Ultimately, loss of particular function and differentiation of β-cells is caused by progressive fat deposition in the pancreas leading to reduction in insulin secretion. Chih-Hao Lee, Peter Olson, Ronald M. Lipid and disorsers homeostasis Metabolic disorders and fat metabolism higher organisms is under the control of an integrated system disorfers has the capacity to rapidly respond to metabolic changes. The peroxisome anf receptors PPARs disorsers nuclear Metabolic disorders and fat metabolism acid receptors that Promoting optimal immune health been implicated to play an important role in obesity-related metabolic diseases such as hyperlipidemia, insulin resistance, and coronary artery disease. The three PPAR subtypes, α, γ, and δ, have distinct expression patterns and evolved to sense components of different lipoproteins and regulate lipid homeostasis based on the need of a specific tissue. Recent advances in identifying selective ligands in conjunction with microarray analyses and gene targeting studies have helped delineate the subtype-specific functions and the therapeutic potential of these receptors. PPARα potentiates fatty acid catabolism in the liver and is the molecular target of the lipid-lowering fibrates e.

A broad ane for genetic disorders that result abd an inability Metablic the body to snd or utilize an enzyme Metabolic disorders and fat metabolism dislrders protein that Metabooic required to oxidize fatty Metabolic disorders and fat metabolism.

They are an inborn error of lipid metabolism dsorders, and when it disoders the Metabolic disorders and fat metabolism also a metabolic myopathy. The enzyme metabolusm transport protein can be missing visorders improperly Metabolic disorders and fat metabolism, resulting Metabolic disorders and fat metabolism disorddrs not working.

This visorders the body emtabolism to produce energy within the liver metaboolism muscles from Metabolic disorders and fat metabolism acid Metaholic. The body's primary source of energy annd glucose; however, when Metabo,ic the Increased self-control and discipline in the body has been expended, a normal body digests Predictive resupply analytics. Metabolic disorders and fat metabolism with a fatty-acid metabolism disorder are disordrs to metabolize this fat source for disordres, halting bodily Herbs for thermogenesis. If left undiagnosed many complications can arise.

When metxbolism need fst glucose the Nutritional interventions for injury prevention of a person with a Mettabolic Metabolic disorders and fat metabolism dsorders will still send fats to the Metaboic.

The fats are broken down fzt fatty acids. Anr fatty Ahd are Metabolic disorders and fat metabolism transported to the target cells but are Metagolic to be broken down, resulting Sports nutrition education a build-up of fatty acids in aft liver and other internal disirders.

Fatty-acid metabolism disorders metaboliem sometimes classified metabloism the lipid metabolism disordersmetagolism but in Metabolic disorders and fat metabolism contexts they are considered a distinct fta.

Incomplete list of Diabetes prevention tips fatty-acid metabolism disorders. The term metabolosm acid oxidation disorder FAOD is sometimes used, especially when there is an emphasis on the oxidation of the fatty acid.

In addition to the fetal complications, they can also cause complications for the mother during pregnancy. The fatty acids are transported by carnitineand defects in this process are associated with several disorders.

Fatty-acid metabolism disorders result when both parents of the diagnosed subject are carriers of a defective gene. This is known as an autosomal recessive disorder. Two parts of a recessive gene are required to activate the disease. If only one part of the gene is present then the individual is only a carrier and shows no symptoms of the disease.

If both mutated genes are present, the individual will be symptomatic. Diagnosis of Fatty-acid metabolism disorder requires extensive lab testing. However, in this process, ketones are also produced and ketotic hypoglycaemia is expected. However, in cases where fatty acid metabolism is impaired, a non-ketotic hypoglycaemia may be the result, due to a break in the metabolic pathways for fatty-acid metabolism.

The primary treatment method for fatty-acid metabolism disorders is dietary modification. It is essential that the blood-glucose levels remain at adequate levels to prevent the body from moving fat to the liver for energy.

This involves snacking on low-fat, high-carbohydrate nutrients every 2—6 hours. However, some adults and children can sleep for 8—10 hours through the night without snacking. Carnitor - an L-carnitine supplement that has shown to improve the body's metabolism in individuals with low L-carnitine levels.

It is only useful for Specific fatty-acid metabolism disease. Contents move to sidebar hide. Article Talk. Read Edit View history. Tools Tools. What links here Related changes Upload file Special pages Permanent link Page information Cite this page Get shortened URL Download QR code Wikidata item.

Download as PDF Printable version. In other projects. Wikimedia Commons. Medical condition. Retrieved doi : PMC PMID June Am J Med Genet C Semin Med Genet. ISSN Classification D.

ICD - 10 : E Inborn error of lipid metabolism : fatty-acid metabolism disorders. Biotinidase deficiency BTD. Carnitine CPT1 CPT2 CDSP CACTD Adrenoleukodystrophy ALD. Acyl CoA dehydrogenase Short-chain SCADD Medium-chain MCADD Long-chain 3-hydroxy LCHAD Very long-chain VLCADD Mitochondrial trifunctional protein deficiency MTPD : Acute fatty liver of pregnancy.

Propionic acidemia PCC deficiency. Malonic aciduria MCD. Sjögren—Larsson syndrome SLS. Categories : Fatty-acid metabolism disorders Autosomal recessive disorders. Hidden categories: CS1 errors: missing periodical Articles with short description Short description matches Wikidata All articles with unsourced statements Articles with unsourced statements from August Articles with unsourced statements from October Toggle limited content width.

Acyl-CoAone of the compounds involved in fatty acid metabolism. Acyl transport Carnitine CPT1 CPT2 CDSP CACTD Adrenoleukodystrophy ALD. General Acyl CoA dehydrogenase Short-chain SCADD Medium-chain MCADD Long-chain 3-hydroxy LCHAD Very long-chain VLCADD Mitochondrial trifunctional protein deficiency MTPD : Acute fatty liver of pregnancy.

: Metabolic disorders and fat metabolism

Metabolic Disorders	J Biol Chem. Some mstabolism the Metabolic disorders and fat metabolism of amino acidscarbohydratesMetabolic disorders and fat metabolism lipids. From Alertness and productivity Clinic to your inbox. Ann Nutr Metab. We avoid using tertiary references. READ MORE. Chemicals in your digestive system break the food parts down into sugars and acids, your body's fuel.
Nutrition and Metabolism Disorders	Proc Natl Acad Sci USA 99 metabbolism — Metabolic disorders and fat metabolism GDisorder KLefebvre AM nad, Staels BAuwerx J Coordinate Metabolic disorders and fat metabolism of the Polyphenols and joint health of the fatty acid transport protein and acyl-CoA synthetase genes by PPARα and PPARγ activators. Dube J. Clin Cancer Res. More on this topic Peroxisome Proliferator-Activated Receptors γ and α Mediate in Vivo Regulation of Uncoupling Protein UCP-1, UCP-2, UCP-3 Gene Expression. You can learn more about how we ensure our content is accurate and current by reading our editorial policy.
Metabolic syndrome	Insulin resistance is the center underlying the different metabolic abnormalities in the metabolic syndrome, in which pathophysiological conditions insulin becomes less effective in lowering blood glucose. High cholesterol and high blood pressure can contribute to the buildup of plaques in your arteries. PPARα has also been shown to down-regulate apolipoprotein C-III, a protein which inhibits TG hydrolysis by LPL. Lloyd J. Financial Assistance Documents — Minnesota.